137 search results for: Clinical Management
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
Partnering With Patients: Scores That Matter in CRSwNP
Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
GOLD Diagnosis and Assessment of COPD
This short video presentation outlines the diagnosis and assessment of COPD according to the GOLD report, focusing on clinical features and assessment goals.
EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Join Professor Joaquim Mullol for a discussion of the emerging concept of clinical remission in CRSwNP.
Indirect Treatment Comparison of Biologics Approved for CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.
How Can FeNO Measurement Improve Severe Asthma Management?
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.
How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz
Join Dr. Miguel Lanz as he explains, in Spanish, the clinical utility of FeNO as a biomarker in severe asthma.
Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind
Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
Emerging Data on Advanced Systemic Treatments for Children With AD
This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga reviewing the systemic treatment landscape for children under 12 years of age with AD in the EU. Dr. Baselga also discusses the latest clinical data on the use of baricitinib in pediatric patients aged 2 to 17 years, and both clinical and real-world data on the efficacy and safety of dupilumab in pediatric patients with AD aged as young as 6 months.
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
This video presentation of the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Eulàlia Baselga, Dr. Amy Paller, and Prof. Lisa Weibel. The faculty investigate the inflammatory processes driven by type 2 cytokines that lead to the local and systemic clinical effects of AD, the potential benefits of treating children with AD early in the disease course, and the emerging clinical and real-world data on the use of advanced systemic treatments for children with AD.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.
